Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, Netherlands.
Lancet. 2011 Jun 18;377(9783):2115-26. doi: 10.1016/S0140-6736(11)60243-2.
Osteoarthritis is thought to be the most prevalent chronic joint disease. The incidence of osteoarthritis is rising because of the ageing population and the epidemic of obesity. Pain and loss of function are the main clinical features that lead to treatment, including non-pharmacological, pharmacological, and surgical approaches. Clinicians recognise that the diagnosis of osteoarthritis is established late in the disease process, maybe too late to expect much help from disease-modifying drugs. Despite efforts over the past decades to develop markers of disease, still-imaging procedures and biochemical marker analyses need to be improved and possibly extended with more specific and sensitive methods to reliably describe disease processes, to diagnose the disease at an early stage, to classify patients according to their prognosis, and to follow the course of disease and treatment effectiveness. In the coming years, a better definition of osteoarthritis is expected by delineating different phenotypes of the disease. Treatment targeted more specifically at these phenotypes might lead to improved outcomes.
骨关节炎被认为是最常见的慢性关节疾病。由于人口老龄化和肥胖症的流行,骨关节炎的发病率正在上升。疼痛和功能丧失是导致治疗的主要临床特征,包括非药物治疗、药物治疗和手术治疗。临床医生认识到,骨关节炎的诊断是在疾病过程的晚期确立的,也许已经太晚了,无法从疾病修饰药物中获得太多帮助。尽管过去几十年一直在努力开发疾病标志物,但仍需要改进影像学程序和生化标志物分析,并可能通过更具体和敏感的方法进行扩展,以可靠地描述疾病过程,在早期诊断疾病,根据预后对患者进行分类,并跟踪疾病过程和治疗效果。在未来几年,通过描绘疾病的不同表型,预计对骨关节炎有更好的定义。针对这些表型更有针对性的治疗可能会带来更好的结果。
Lancet. 2011-6-18
Clin Evid. 2002-12
Am Fam Physician. 2000-3-15
Presse Med. 2002-9-14
Clin Evid. 2002-6
Arthritis Care Res (Hoboken). 2014-6
J Rheumatol. 2000-4
Clin Evid. 2003-12
Medicine (Baltimore). 2025-8-15
Front Immunol. 2025-7-16
Pharmaceuticals (Basel). 2025-7-19